$0.8979
At close: May 1 EDT
$0.9249
0.033.01%
Pre-Market: 5:12 AM EDT
Comments
Loading...
Atossa Therapeutics Analyst Ratings and Price Targets | NASDAQ:ATOS | Benzinga
Atossa Therapeutics Inc has a consensus price target of $7.13 based on the ratings of 3 analysts. The high is $7.25 issued by Ascendiant Capital on April 21, 2025. The low is $7 issued by HC Wainwright & Co. on March 26, 2025. The 3 most-recent analyst ratings were released by Ascendiant Capital, HC Wainwright & Co., and HC Wainwright & Co. on April 21, 2025, March 26, 2025, and March 12, 2025, respectively. With an average price target of $7.08 between Ascendiant Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 665.85% upside for Atossa Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Ascendiant Capital
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Atossa Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/21/2025 | Buy Now | 683.87% | Ascendiant Capital | Edward Woo56% | $7 → $7.25 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | 656.84% | HC Wainwright & Co. | Emily Bodnar38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 656.84% | HC Wainwright & Co. | Emily Bodnar38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2025 | Buy Now | 656.84% | HC Wainwright & Co. | Emily Bodnar38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 656.84% | HC Wainwright & Co. | Emily Bodnar38% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Reiterates | Buy → Buy | Get Alert |
| 12/09/2024 | Buy Now | 656.84% | Ascendiant Capital | Edward Woo56% | $6.5 → $7 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 656.84% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $7 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 548.72% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 548.72% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 602.78% | Ascendiant Capital | Edward Woo56% | $6.25 → $6.5 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 548.72% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 548.72% | HC Wainwright & Co. | Emily Bodnar38% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen54% | — | Reiterates | → Overweight | Get Alert |
| 06/06/2024 | Buy Now | 575.75% | Ascendiant Capital | Edward Woo56% | $6 → $6.25 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen54% | — | Reiterates | → Overweight | Get Alert |
| 05/13/2024 | Buy Now | 548.72% | HC Wainwright & Co. | Emily Bodnar38% | $4 → $6 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 332.48% | HC Wainwright & Co. | Emily Bodnar38% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 332.48% | HC Wainwright & Co. | Emily Bodnar38% | $4 → $4 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 332.48% | HC Wainwright & Co. | Emily Bodnar38% | → $4 | Initiates | → Buy | Get Alert |
| 09/08/2023 | Buy Now | 440.6% | Cantor Fitzgerald | Louise Chen54% | → $5 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Atossa Therapeutics (ATOS) stock?
The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by Ascendiant Capital on April 21, 2025. The analyst firm set a price target for $7.25 expecting ATOS to rise to within 12 months (a possible 683.87% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atossa Therapeutics (ATOS)?
The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by Ascendiant Capital, and Atossa Therapeutics maintained their buy rating.
When was the last upgrade for Atossa Therapeutics (ATOS)?
There is no last upgrade for Atossa Therapeutics
When was the last downgrade for Atossa Therapeutics (ATOS)?
There is no last downgrade for Atossa Therapeutics.
When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.
Is the Analyst Rating Atossa Therapeutics (ATOS) correct?
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a maintained with a price target of $7.00 to $7.25. The current price Atossa Therapeutics (ATOS) is trading at is $0.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
